Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE).

Autor:	Stærke NB; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark ninase@rm.dk.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Reekie J; Center of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Kobenhavn, Denmark., Johansen IS; Department of Infectious Diseases, Odense Universitetshospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Nielsen H; Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Benfield T; Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Wiese L; Department of Medicine, Zealand University Hospital, Roskilde, Denmark., Søgaard OS; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Tolstrup M; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Iversen KK; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Cardiology and Department of Emergency Medicine, Herlev Hospital, Herlev, Denmark., Tarp B; Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark., Larsen FD; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Larsen L; Department of Infectious Diseases, Odense Universitetshospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Lindvig SO; Department of Infectious Diseases, Odense Universitetshospital, Odense, Denmark., Holden IK; Department of Infectious Diseases, Odense Universitetshospital, Odense, Denmark., Iversen MB; Department of Medicine, Zealand University Hospital, Roskilde, Denmark., Knudsen LS; Department of Medicine, Zealand University Hospital, Roskilde, Denmark., Fogh K; Department of Cardiology and Department of Emergency Medicine, Herlev Hospital, Herlev, Denmark., Jakobsen ML; Center of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Kobenhavn, Denmark., Traytel AK; Center of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Kobenhavn, Denmark., Ostergaard L; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Lundgren J; Center of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Kobenhavn, Denmark.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2022 Dec 30; Vol. 12 (12), pp. e069065. Date of Electronic Publication: 2022 Dec 30.
DOI:	10.1136/bmjopen-2022-069065
Abstrakt:	Purpose: The ENFORCE cohort is a national Danish prospective cohort of adults who received a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as part of the Danish National SARS-CoV-2 vaccination programme. It was designed to investigate the long-term effectiveness, safety and durability of SARS-CoV-2 vaccines used in Denmark. Participants: A total of 6943 adults scheduled to receive a SARS-CoV-2 vaccine in the Danish COVID-19 vaccination programme were enrolled in the study prior to their first vaccination. Participants will be followed for a total of 2 years with five predetermined follow-up visits and additional visits in relation to any booster vaccination. Serology measurements are performed after each study visit. T-cell immunity is evaluated at each study visit for a subgroup of 699 participants. Safety information is collected from participants at visits following each vaccination. Data on hospital admissions, diagnoses, deaths and SARS-CoV-2 PCR results are collected from national registries throughout the study period. The median age of participants was 64 years (IQR 53-75), 56.6% were women and 23% were individuals with an increased risk of a serious course of COVID-19. A total of 340 (4.9%) participants tested positive for SARS-CoV-2 spike IgG at baseline. Findings to Date: Results have been published on risk factors for humoral hyporesponsiveness and non-durable response to SARS-CoV-2 vaccination, the risk of breakthrough infections at different levels of SARS-CoV-2 spike IgG by viral variant and on the antibody neutralising capacity against different SARS-CoV-2 variants following primary and booster vaccinations. Future Plans: The ENFORCE cohort will continuously generate studies investigating immunological response, effectiveness, safety and durability of the SARS-CoV-2 vaccines. Trial Registration Number: NCT04760132. Competing Interests: Competing interests: NBS declares to have served as investigator on studies sponsored by Pfizer, Gilead, Bavarian and Sanofi Pasteur. HN declares receiving a grant from Novo Nordisk Foundation and to have been on advisory boards for MSD and GSK. TB declares receipt of unrestricted research or travel grants from GSK, Pfizer, Gilead Sciences, MSD; and being principal investigator on trials conducted by Boehringer Ingelheim, Roche, Novartis, Kancera, Pfizer, MSD and Gilead; Board member on Pentabase, and advisory board member for MSD, Gilead, Pfizer, GSK, Janssen and AstraZeneca; consulting fees from GSK and Pfizer; receiving donation of study drug from Eli Lilly; and receiving honorarium for lectures from GSK, Pfizer, Gilead Sciences, Boehringer Ingelheim, AbbVie and AstraZeneca. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu